Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Rebecca Shatsky

Breast Oncology · UCSD

View

Dr. Robert Bast

Breast Oncology · MD Anderson Cancer Center

View

Dr. Sara Tolaney

Breast Oncology · Dana-Farber Cancer Institute

View

Dr. Jason Mouabbi

Breast Oncology · MD Anderson Cancer Center

View

Dr. Matthew Kurian

Breast Oncology · St Elizabeth Healthcare

View

Dr. Sarah Premji

Breast Oncology

View

Dr. Nerea Lopetegui-Lia

Breast Oncology · OSUMC

View

Dr. Allison Kurian

Breast Oncology · SU

View

Dr. Minhtri Nguyen

Breast Oncology · Advisor

View

Dr. Neil Iyengar

Breast Oncology · Emory University

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    The Association of Clinical Stage at Presentation with Overall Survival of Patients who have HER2-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy.

    Aug 14, 2025DOI: 10.1245/s10434-025-18050-wJournal ArticleASO

    Written by: Nara L TashjianTanya L HoskinRoberto A Leon-FerreJudy C Boughey

    Find these authors on Roon

    RL
    Dr. Roberto Leon-Ferre
    Breast Oncology · Mayo Clinic College of Medicine

    Summary

    BACKGROUND: Pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) in human epidermal growth factor receptor 2-positive (HER2+) breast cancer is associated with improved survival. This study evaluated the association of disease extent at presentation and response to NAC with overall survival (OS) in HER2+ breast cancer.METHODS: Patients with clinical stage I to III HER2+ breast cancer (2013-2020) who underwent NAC and received HER2-targeted therapy were identified from the National Cancer Database. Overall survival was assessed by clinical stage at presentation and chemotherapy response, stratified by hormone receptor (HR) status using multivariable Cox proportional hazards regression.RESULTS: The study included 57,671 patients. Among the patients with pCR, OS at 5 years was 98% for stage I, 97% for stage II, and 91% for stage III disease (p < 0.001). Among patients with residual disease, OS at 5 years was 95% for stage I, 91% for stage II, and 80% for stage III disease (p < 0.001). Multivariable analysis showed that stage III HR-/HER2+ disease with pCR did not have OS different from stage I breast cancer with residual disease (hazard ratio, 1.17; p = 0.34). Stage II HR+/HER2+ disease with pCR did not have OS different from stage I breast cancer with residual disease (hazard ratio, 0.94; p = 0.61), and stage III disease with pCR had worse OS (hazard ratio, 1.90; p < 0.001).CONCLUSIONS: Among the patients who had HER2+ breast cancer treated with NAC, the clinical stage at presentation was associated with OS for those with pCR and residual disease. Patients with stage III HER2+ breast cancer and those with stage II HR+/HER2+ breast cancer who achieve pCR could benefit from further studies that evaluate potential escalation of adjuvant therapies.
    RLDr. Roberto Leon-Ferre
    Leading Voice

    Dr. Roberto Leon-Ferre

    Medical Oncology · Breast Oncology
    Mayo Clinic
    roberto
    Rochester, MN, USA